The product incorporates Circ Pharma’s drug delivery technology enabling once daily dosing. Circ’s technology provides for minimized delivery to the body during sleeping hours, acceleration of drug absorption immediately prior to the waking hours and the subsequent maintenance of efficacious drug levels for the remainder of the waking hours.
Circ has successfully completed Phase I testing on the product. Circ Pharma intends to seek a licensing partner for worldwide commercial distribution of the product.
The agreement with Elan provides that Elan support the continued formulation and manufacturing activities required to seek regulatory approval for this product in the US and elsewhere.
Margot Foynes, chief technical officer of Circ Pharma, said: “Elan’s extensive experience, know-how and technology for the development and manufacture of scheduled products for the US market will ensure that we can quickly and efficiently complete all the development and clinical activities required for Chrono Tramadol.”